Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.36B +23.9% |
| Revenue (ttm) | 52.89M -8.1% |
| Net Income | -426.14M |
| EPS | -3.35 |
| Shares Out | 140.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,416,703 |
| Open | 10.45 |
| Previous Close | 10.55 |
| Day's Range | 9.67 - 10.51 |
| 52-Week Range | 7.95 - 18.48 |
| Beta | 1.82 |
| Analysts | Buy |
| Price Target | 22.78 (+134.85%) |
| Earnings Date | Nov 5, 2026 |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $22.78, which is an increase of 134.85% from the latest price.
News
Intellia Therapeutics presents additional data for lonvoguran ziclumeran
Intellia Therapeutics (NTLA) announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will...
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Transcript: Study update
HAELO and integrated follow-up data showed substantial attack reduction, durable control through four years, and freedom from LTP in all 93 participants at last follow-up. FDA set a March 10, 2027 action date, while launch planning targets broad coverage and full ramp by month 12 if approved.
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics price target raised to $9 from $8 at JPMorgan
JPMorgan raised the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $8 and keeps an Underweight rating on the shares.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics price target lowered to $16 from $17 at BofA
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $16 from $17 and keeps a Neutral rating on the shares.
Intellia Therapeutics reports Q3 EPS (91c), consensus (79c)
Reports Q3 revenue $7.16M, consensus $9.77M. “This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead,” said John Leonard, Intellia…
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and ...
Intellia Therapeutics Earnings release: Q3 2026
Intellia Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Intellia Therapeutics Quarterly report: Q3 2026
Intellia Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial Presentation at ISA on Nov. ...
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics appoints Jing Marantz as chief medical officer
Intellia Therapeutics (NTLA) announced the appointment of Jing Marantz as executive VP and chief medical officer, effective October 26. Marantz will lead the company’s translational, development, regu...
Intellia Therapeutics Appoints Jing L. Marantz, M.D.
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Barclays starts Intellia at Underweight on expected commercial headwinds
Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating and $8 price target The firm sees headwinds for the company’s late-stage assets in hereditary angioedema and tran...
Intellia Therapeutics initiated with an Underweight at Barclays
Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating and $8 price target
Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today
20:23 EDT Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics (NTLA) today
Cathie Wood’s ARK Investment buys 411K shares of Intellia Therapeutics today
20:17 EDT Cathie Wood’s ARK Investment buys 411K shares of Intellia Therapeutics (NTLA) today
Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics today
20:44 EDT Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing in vivo gene editing with late-stage programs for HAE and TTR, expecting FDA approval for its HAE therapy by March 10. Strong efficacy and safety data support broad market potential, with a targeted commercial launch and robust financial runway enabling future pipeline investments.
Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today
20:05 EDT Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics price target raised to $13 from $12 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Intellia Therapeutics (NTLA) to $13 from $12 and keeps a Neutral rating on the shares. The firm notes the FDA…
Intellia Therapeutics announces FDA acceptance of lonvo-z BLA
Intellia Therapeutics (NTLA) announced the FDA has accepted the biologics license application for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.